Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Conformis stock | $1.2

Learn how to easily invest in Conformis stock.

Conformis Inc is a medical devices business based in the US. Conformis shares (CFMS) are listed on the NASDAQ and all prices are listed in US Dollars. Conformis employs 259 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Conformis

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CFMS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Conformis stock price (NASDAQ: CFMS)

Use our graph to track the performance of CFMS stocks over time.

Conformis shares at a glance

Information last updated 2021-10-23.
Latest market close$1.20
52-week range$0.60 - $1.96
50-day moving average $1.43
200-day moving average $1.19
Wall St. target price$2.17
PE ratio 10.6723
Dividend yield N/A (0%)
Earnings per share (TTM) $0.12

Buy Conformis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
$0
0%
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Conformis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Conformis price performance over time

Historical closes compared with the close of $1.2 from 2021-10-26

1 week (2021-10-21) -4.76%
1 month (2021-09-28) -11.11%
3 months (2021-07-28) -17.81%
6 months (2021-04-28) 21.58%
1 year (2020-10-27) 73.91%
2 years (2019-10-25) -40.00%
3 years (2018-10-26) 33.33%
5 years (2016-10-27) 7.9

Is Conformis under- or over-valued?

Valuing Conformis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Conformis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Conformis's P/E ratio

Conformis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Conformis shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Conformis's PEG ratio

Conformis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.21. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Conformis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Conformis's EBITDA

Conformis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.6 million.

The EBITDA is a measure of a Conformis's overall financial performance and is widely used to measure a its profitability.

Conformis financials

Revenue TTM $103 million
Operating margin TTM 7.09%
Gross profit TTM $33.7 million
Return on assets TTM 3.86%
Return on equity TTM 20.47%
Profit margin 13.33%
Book value $0.68
Market capitalisation $236.2 million

TTM: trailing 12 months

Shorting Conformis shares

There are currently 4.6 million Conformis shares held short by investors – that's known as Conformis's "short interest". This figure is 30% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Conformis shares can be evaluated.

Conformis's "short interest ratio" (SIR)

Conformis's "short interest ratio" (SIR) is the quantity of Conformis shares currently shorted divided by the average quantity of Conformis shares traded daily (recently around 3.3 million). Conformis's SIR currently stands at 1.42. In other words for every 100,000 Conformis shares traded daily on the market, roughly 1420 shares are currently held short.

However Conformis's short interest can also be evaluated against the total number of Conformis shares, or, against the total number of tradable Conformis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Conformis's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Conformis shares in existence, roughly 30 shares are currently held short) or 0.0257% of the tradable shares (for every 100,000 tradable Conformis shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Conformis.

Find out more about how you can short Conformis stock.

Conformis share dividends

We're not expecting Conformis to pay a dividend over the next 12 months.

Conformis share price volatility

Over the last 12 months, Conformis's shares have ranged in value from as little as $0.602 up to $1.955. A popular way to gauge a stock's volatility is its "beta".

CFMS.US volatility(beta: 1.43)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Conformis's is 1.4349. This would suggest that Conformis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Conformis overview

Conformis, Inc. , a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Frequently asked questions

What percentage of Conformis is owned by insiders or institutions?
Currently 2.993% of Conformis shares are held by insiders and 56.178% by institutions.
How many people work for Conformis?
Latest data suggests 259 work at Conformis.
When does the fiscal year end for Conformis?
Conformis's fiscal year ends in December.
Where is Conformis based?
Conformis's address is: 600 Technology Park Drive, Billerica, MA, United States, 01821
What is Conformis's ISIN number?
Conformis's international securities identification number is: US20717E1010
What is Conformis's CUSIP number?
Conformis's Committee on Uniform Securities Identification Procedures number is: 20717E101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site